Company: BIAF
Filing Date: 2025-10-09
Form Type: 424B5
Source: 0001493152-25-017591
Chunk: 82

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-09
Form: 424B5
Chunk 82
---
 Markets or national securities exchanges, and the inability of registered broker-dealers to make a market in our Common Stock, which may reduce our stock price.

| 30 |

General Risks

We are an “emerging growth company” and a “smaller reporting company,” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our Units less attractive to investors.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “ JOBS Act”), and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

| ● | being                                                                                                                                    
 permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, 
 with correspondingly reduced MD&A disclosure;                                                                                            |
| ● | not                                                                                                                                      
 being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;   |
| ● | not                                                                                                                                      
 being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board or a supplement       
 to the auditor’s report providing additional information about the audit and the financial statements;                                   |
| ● | reduced                                                                                                                                  
 disclosure obligations regarding executive compensation; and                                                                             |
| ● | not                                                                                                                                      
 being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute      
 payments not previously approved.                                                                                                        |

In addition, as an “emerging growth company” the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. We will remain an emerging growth company until the earlier of: (i) the last day of the fiscal year (1) following the fifth anniversary of the completion of our initial public offering, (2) in which we have total annual gross revenue of at least $1.235 billion, or (3) in which we are deemed to be a large accelerated filer, which means the market value